Oral miltefosine for Indian post‐kala‐azar dermal leishmaniasis: a randomised trial
Open Access
- 8 November 2012
- journal article
- research article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 18 (1), 96-100
- https://doi.org/10.1111/tmi.12015
Abstract
Objective Standard treatment of Indian post‐kala‐azar dermal leishmaniasis (PKDL) is unsatisfactory because to achieve therapeutic effectiveness, heroic courses of parenteral and toxic agents have to be administered. Our objective was to evaluate oral miltefosine for its potential to provide effective as well as tolerable treatment for this disease. Method Open‐label, randomised, parallel‐group multicentric trial. Miltefosine, 100 mg/day to all but one patient, was administered for 12 weeks or 8 weeks, with a target of 18 patients in each treatment group. Key endpoints were tolerance during treatment and efficacy at 12 months of follow‐up. Results The ITT and per‐protocol cure rates after 12 months of follow‐up for patients receiving 12 weeks of therapy were 78% (14 of 18 patients: 95% CI = 61–88%) and 93% (14 of 15 patients: 95% CI = 71–95%), respectively, after 12 months of follow‐up. The ITT and per‐protocol cure rates for patients receiving 8 weeks of therapy were 76% (13 of 17 patients: 95% CI = 53–90%) and 81% (13 of 16 patients: 95% CI = 57–93%), respectively. Gastrointestinal and other adverse events were rare. Conclusions This study suggests that oral miltefosine for 2–3 months can be considered a treatment of choice for Indian PKDL.Keywords
This publication has 12 references indexed in Scilit:
- Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasisBritish Journal of Dermatology, 2011
- Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, BrazilThe American Journal of Tropical Medicine and Hygiene, 2011
- Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled TrialPLoS Neglected Tropical Diseases, 2010
- Efficacy of Miltefosine for the Treatment of American Cutaneous LeishmaniasisThe American Journal of Tropical Medicine and Hygiene, 2010
- Post‐kala‐azar dermal leishmaniasis – an overviewInternational Journal of Dermatology, 2010
- Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral LeishmaniasisThe Journal of Infectious Diseases, 2007
- Miltefosine for New World Cutaneous LeishmaniasisClinical Infectious Diseases, 2004
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002
- Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post kala azar dermal leishmaniasisPathogens and Global Health, 1997